Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
All content for ACE OncoCast is the property of ACE Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)
ACE OncoCast
13 minutes
2 years ago
Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with collaboration between surgeons, medical oncologists, radiation oncologists, pathologists and other specialists. Bladder preservation is an alternative to cystectomy for patients deemed unfit for surgery. The MDT board should develop a treatment strategy...
ACE OncoCast
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
